Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials (2022) Pfaffendorf C, Vonthein R, Krockenberger-Ziegler K, Dellas K, Schreiber A, Uhlemann D, Dinges S, et al. Journal article Mammographic density and prognosis in primary breast cancer patients (2021) Heindl F, Fasching P, Hein A, Hack C, Heusinger K, Gaß P, Pöschke P, et al. Journal article Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)) (2021) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article, Erratum Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study (2020) Fasching P, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, et al. Journal article Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients (2020) Hack C, Häberle L, Brucker SY, Janni W, Volz B, Löhberg C, Hartkopf AD, et al. Journal article Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study (2019) Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus , Foerster F, Grischke EM, et al. Journal article Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study (2019) Deniz M, Degregorio A, Degregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, et al. Journal article Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry (2018) Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, et al. Journal article